QIAGEN reports results for second quarter of 2019; updates full-year 2019 outlook due to decision to restructure China NGS partnership

Venlo, the Netherlands, July 24, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results of operations for the second quarter of 2019, achieving the outlook set for net sales growth and adjusted earnings per share at constant exchange rates (CER). QIAGEN also announced that it intends to restructure the current format... Read more

Delaware District Court Grants Bio-Rad’s Motion for Permanent Injunction Against 10X Genomics

ate: 07/24/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announces that today the Delaware District Court granted Bio-Rad’s motion for permanent injunction against 10X Genomics from making any sales of infringing products to new customers and granting Bio-Rad’s request for supplemental damages and... Read more

Oxford Nanopore prevails for fourth time in patent hearing

Wed 17th July 2019 Oxford Nanopore has prevailed once again following the decision yesterday by the European Patent Office (EPO) to revoke a second PacBio European Patent, EP3170904. This decision is consistent with that of an earlier EPO decisionrevoking PacBio European Patent EP3045542, as well as rulings from the ITC and US Court of Appeal that the claims of the... Read more

MTS Systems Announces Executive Leadership Promotions

EDEN PRAIRIE, Minn., July 1, 2019 /PRNewswire/ — MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems, motion simulators and sensors, today announced the promotion of three senior executives to the position of Executive Vice President.  They include:  Mr. Brian Ross, Chief Financial Officer; Mr. Dave Hore, President of MTS Sensors,... Read more

Century Therapeutics Launches with $250M Financing for iPSC Allogeneic Cell Therapy Platform

Tokyo, June 1, 2019 ― FUJIFILM Corporation (President: Kenji Sukeno) will accelerate the development of next-generation cancer immunotherapeutic drug candidates by harnessing the self-renewal potential of allogenic induced pluripotent stem cells (iPSCs). FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human iPSCs and tissue-specific cells differentiated from iPSCs, and Versant Venture Management,... Read more

Illumina Files Patent Infringement Suits Related to BGI in Switzerland, Turkey and the US

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed three additional patent infringement suits relating to BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents. The first complaint was filed against Complete Genomics, Inc. and other BGI entities in the United States District Court for the Northern District of California... Read more

CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer

Basel, 28 June 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer... Read more